SecBot SecBot
8-K ·Filed Nov 9, 2026

IONS

IONIS PHARMACEUTICALS INC
BEARISH
Impact 6/10
Horizonweeks Processed7d 16h ago SEC0001140361-26-042598
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The TRYNGOLZA launch miss is the key negative surprise, cutting the flagship product's 2026 outlook in half. Monitor Q4 2026 TRYNGOLZA sales and any further guidance changes; the DAWNZERA and ZANVASTRO launches and partnered pipeline (HIBSAGO, sefaxersen, ulefnersen) provide offsetting catalysts.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

IONS drug pipeline →

sefaxersen

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
Regulatory submission is expected soon — Roche plans to share data with health authorities to seek approval. If filed under standard review, potential approval could come in 2027-2028. The timeline depends on Roche's submission strategy and whether the FDA grants expedited review pathways.
Next catalyst
None dated

What to watchThe Phase 3 success is a major derisking event, but the stock hasn't rallied, watch for regulatory submission timing from Roche and the week 105 eGFR data, which will determine the full approval path. The stock near its 52-week low with strong analyst support and a deep pipeline (bepirovirsen/HIBSAGO just approved, zilganersen PDUFA passed) creates an asymmetric risk/reward for investors willing to wait for regulatory milestones.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$31.00
T+0 close · Nov 9, 2026 · via day close
Latest settled
−9.65%
T+5 · $28.01
Vs SPY
−7.95%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $31.00entry
  2. T+1 · 7d ago −9.06%α −8.70% · $28.19
  3. T+5 · 16h ago −9.65%α −7.95% · $28.01
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Total revenue, DAWNZERA guidance, operating loss and cash guidance were reaffirmed.

Key Financial Metrics

Revenue
$243.0M
est $184.4M · +31.8% · +54.8% YoY
Guidance
$875M-$900M
maintained

Key Facts

  • TRYNGOLZA 2026 product sales guidance lowered to ~$50M from $100-110M
  • DAWNZERA 2026 product sales guidance reaffirmed at $110-120M
  • Total revenue guidance reaffirmed at $875-900M
  • Cash and short-term investments $1.9B as of Sep 30, 2026
  • ZANVASTRO (zilganersen) launched for Alexander disease with first patients dosed
  • SPINRAZA royalties $69M in Q3 2026, up 23% YoY
  • Positive Phase 3 data for sefaxersen (IgAN) and ulefnersen (FUS-ALS)

Financial Impact

TRYNGOLZA product sales guidance cut by ~$50-60M from prior $100-110M to ~$50M; total revenue guidance unchanged at $875-900M

revenueproduct sales guidance

Risk Factors

  • TRYNGOLZA sHTG launch may continue to underperform expectations
  • Operating expenses rising with commercial investments; cash burn $800M+ in 9 months
  • Pipeline setbacks possible (pelacarsen Lp(a) HORIZON data not achieved in 2026)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
84% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-042598
Document: ef20085128_8k.htm0001140361-26-042598
Document: 0001140361-26-042598-index-headers.html0001140361-26-042598
Document: 0001140361-26-042598-index.html0001140361-26-042598
Document: 0001140361-26-042598.txt0001140361-26-042598
8-K Data (Synthetic)0001140361-26-042598

Track record

26 reports on IONS

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +32.25% at T+60 after the Jul 9, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bearish 6/10 Viewing Entry $31.00 to $28.01 Now $28.01 +9.65% ▲ +9.65% +7.95% vs SPY
  2. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $44.90 to $40.15 Now $28.01 −37.62% ▼ −10.58% −9.87% vs SPY
  3. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $42.93 to $43.52 Now $28.01 −34.75% ▲ +1.37% +1.93% vs SPY
  4. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
  5. Oct 21, 202626d ago Institutional Cluster Mixed 3/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
  6. Sep 23, 20267w ago 8-K Bullish 7/10 Entry $43.93 to $44.65 Now $28.01 −36.24% ▲ +1.64% +2.31% vs SPY
  7. Sep 4, 202610w ago 8-K Bearish 7/10 Entry $56.71 to $47.25 Now $28.01 +50.61% ▲ +16.68% +15.56% vs SPY
  8. Sep 4, 202610w ago 8-K Bullish 7/10 Entry $58.09 to $51.44 Now $28.01 −51.78% ▼ −11.45% −10.24% vs SPY
  9. Jul 31, 202615w ago Insider Buy Neutral 4/10 Entry $54.49 to $56.94 Now $28.01 −48.60% ▲ +4.50% +2.47% vs SPY
  10. Jul 29, 202615w ago 8-K Neutral 5/10 Entry $54.04 to $54.19 Now $28.01 −48.17% ▲ +0.28% −5.25% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (10h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026